Study to Evaluate Induction Chemotherapy Using Docetaxel, Cisplatin and Fluorouracil in Concurrence With Intensity-modulated Radiotherapy for Local Recurrent Nasopharyngeal Carcinoma (NPC)

Inclusion criteria: * Recurrent T3N0-N1M0 NPC (by AJCC/UICC 6th edition) and at least 1 year from the end of last primary course of radiotherapy * Age \> 18 to \< 70 years * Performance status: \< 1 by ECOG System (Appendix I) * Adequate bone marrow \& renal function * Patients having Bilirubin =\< 1.5 x ULN, ASAT \& ALST=\< 1.5 x ULN, Serum creatinine=\< 1.25 x ULN and / or Creatinine clearance \>= 60ml/min * Patients having WBC \>= 3x10e9/L, Neutrophils 1.8x10e9/L, Platelets \>= 100 x10e9/L,Hemoglobin \>=10g/dL * Signed written informed consent * Patients must have at least one measurable lesion Exclusion Criteria: * Use of investigational agent within the past 28 days * Pre-treatment with an anti-EGFR drug * Severe cardiac disease such as heart failure, coronary artery disease or myocardial infarction within the last 12 months * History of severe pulmonary diseases * Active infection or other systemic disease under poor control * Uncontrolled chronic neuropathy * Know grade 3 or 4 allergic reaction to any of the components of the treatment * Estimated life expectancy is less than 3 months * Pregnancy or breast feeding